Floatz logo

Vinorelbine

Pancreatic Ductal Carcinoma

University Health Network, TorontoPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Pancreatic Ductal Carcinoma cohort.

Asset / SponsorPhaseRating
JAB 3312
Allist Pharmaceuticals, Inc.
Phase 1/2B
Trastuzumab Emtansine
University Health Network, Toronto
Phase 2CCC
COLCHICINUM
University Health Network, Toronto
Phase 2CCC
Brigatinib
University Health Network, Toronto
Phase 2CCC
Ceritinib
University Health Network, Toronto
Phase 2CCC

View all 11 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →